Studies using Cantargia's antibodies in models of chronic myeloid leukaemia presented at the American Society of Hematology
Results generated using Cantargia AB’s (”Cantargia”) antibodies, including the product candidate CAN04, are to be presented by Dr Helena Ågerstam of Lund University in an oral session at the American Society of Hematology's (ASH) 58th annual meeting in San Diego on 3-6 December 2016. The presentation focuses on studies in preclinical models of chronic myeloid leukaemia (CML).Cantargia develops the humanised antibody CAN04 against the target molecule Interleukin-1 Receptor Associated Protein (IL1RAP) for the treatment of cancer. Cantargia has previously shown that antibodies targeted against